First approved clinical trial protocol to use retroviral-mediated gene transduction to introduce a marker gene into human tumor-infiltrating lymphocytes (TILs) before their infusion back into five patients with advanced melanoma4.

Demonstrated the feasibility and safety of using retroviral-mediated gene transduction as a method of introducing new genes into the body for human gene therapy4.